6533b859fe1ef96bd12b8109

RESEARCH PRODUCT

Finding the right dose of fulvestrant in breast cancer

Yolanda FernándezIsabel AlvarezMontse MuñozIgnasi TusquetsM. A. SeguíLaura G. EstévezAna Lluch

subject

Clinical Trials as TopicAntineoplastic Agents HormonalDose-Response Relationship DrugEstradiolFulvestrantbusiness.industryAntagonistEstrogen receptorBreast NeoplasmsGeneral MedicinePharmacologymedicine.diseaseEffective dose (pharmacology)Clinical trialSecond lineBreast cancerOncologymedicineHumansFemaleRadiology Nuclear Medicine and imagingbusinessFulvestrantmedicine.drugHormone

description

Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.

yearjournalcountryeditionlanguage
2012-01-04Cancer Treatment Reviews
https://doi.org/10.1016/j.ctrv.2012.06.003